Siren L.L.C. Decreases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Siren L.L.C. reduced its position in Centessa Pharmaceuticals by 1.5%, now owning approximately 2,960,029 shares valued at $42.57 million.
• Several hedge funds, including Janus Henderson Group PLC, made significant increases to their positions in Centessa Pharmaceuticals, highlighting strong institutional interest in the company.
• Analysts have a generally positive outlook on Centessa Pharmaceuticals, with an average price target of $28.10 and numerous firms issuing "buy" ratings.

Siren L.L.C. trimmed its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,960,029 shares of the company's stock after selling 44,648 shares during the period. Centessa Pharmaceuticals accounts for approximately 2.5% of Siren L.L.C.'s investment portfolio, making the stock its 12th biggest holding. Siren L.L.C. owned about 2.22% of Centessa Pharmaceuticals worth $42,565,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd boosted its holdings in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in Centessa Pharmaceuticals in the first quarter valued at $47,000. Barclays PLC boosted its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $162,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded up $0.23 during midday trading on Friday, reaching $16.79. The company had a trading volume of 632,847 shares, compared to its average volume of 1,025,817. The company has a market capitalization of $2.25 billion, a P/E ratio of -9.38 and a beta of 1.47. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $19.09. The firm's fifty day simple moving average is $15.70 and its 200-day simple moving average is $14.44. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total value of $138,600.00. Following the transaction, the insider directly owned 122,279 shares of the company's stock, valued at $1,694,786.94. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $12.63, for a total transaction of $694,650.00. Following the completion of the transaction, the chief executive officer directly owned 221,017 shares in the company, valued at $2,791,444.71. This trade represents a 19.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 171,322 shares of company stock valued at $2,472,814. 7.09% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CNTA shares. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target on the stock. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Truist Financial started coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $30.00 price target on the stock. Chardan Capital reissued a "buy" rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. Finally, Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Friday. They set an "outperform" rating and a $40.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $31.50.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.